Literature DB >> 21716319

Maternal iNOS genetic polymorphisms and hypertensive disorders of pregnancy.

L M Amaral1, A C T Palei, V C Sandrim, M R Luizon, R C Cavalli, G Duarte, J E Tanus-Santos.   

Abstract

Increased expression and activity of inducible nitric oxide synthase (iNOS) may contribute to the pathogenesis of pre-eclampsia (PE) and gestational hypertension (GH). However, no previous study has examined whether genetic polymorphisms in the iNOS gene are associated with PE or GH. We examined whether two functional, clinically relevant iNOS genetic polymorphisms (the C(-1026)A polymorphism, rs2779249, in the promoter region, and the G2087A polymorphism, rs2297518, in exon 16) are associated with GH or with PE. We studied 565 pregnant women: 212 healthy pregnant (HP), 166 pregnant with GH and 187 pregnant with PE. Genotypes were determined by real-time PCR, using the Taqman allele discrimination assay. The PHASE 2.1 program was used to estimate haplotype distributions in the three study groups. We found no significant association between the C(-1026)A polymorphism and PE or GH (P>0.05). However, we found the GA genotype and the A allele for the G2087A polymorphism at higher frequency in PE, but not in GH, compared with HP (P<0.05). The haplotype analysis showed no significant intergroup differences (P>0.05). These findings suggest that iNOS genetic variants may affect the susceptibility to PE, but not to GH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21716319     DOI: 10.1038/jhh.2011.65

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

1.  Nitric oxide synthase gene polymorphisms in functional dyspepsia.

Authors:  Jae Myung Park; Myong-Ki Baeg; Chul-Hyun Lim; Yu Kyung Cho; Myung-Gyu Choi
Journal:  Dig Dis Sci       Date:  2013-10-11       Impact factor: 3.199

2.  Physical activity and epigenetic biomarkers in maternal blood during pregnancy.

Authors:  Sylvia E Badon; Alyson J Littman; Kwun Chuen Gary Chan; Mahlet G Tadesse; Patricia L Stapleton; Theo K Bammler; Tanya K Sorensen; Michelle A Williams; Daniel A Enquobahrie
Journal:  Epigenomics       Date:  2018-10-16       Impact factor: 4.778

3.  Inducible nitric oxide synthase haplotype associated with migraine and aura.

Authors:  Thiago de O S Mansur; Flavia M Gonçalves; Alisson Martins-Oliveira; Jose G Speciali; Fabiola Dach; Riccardo Lacchini; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2012-01-11       Impact factor: 3.396

Review 4.  Pathophysiology and Current Clinical Management of Preeclampsia.

Authors:  Lorena M Amaral; Kedra Wallace; Michelle Owens; Babbette LaMarca
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

5.  Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy.

Authors:  Lorena M Amaral; Luissa Kiprono; Denise C Cornelius; Carrie Shoemaker; Kedra Wallace; Janae Moseley; Gerd Wallukat; James N Martin; Ralf Dechend; Babbette LaMarca
Journal:  Am J Obstet Gynecol       Date:  2014-02-15       Impact factor: 8.661

6.  Inducible Nitric Oxide Synthase Polymorphisms and Nitric Oxide Levels in Individuals with Chronic Periodontitis.

Authors:  Raquel M Scarel-Caminaga; Flávia F Cera; Suzane C Pigossi; Livia S Finoti; Yeon J Kim; Aline C Viana; Rodrigo Secolin; Marcelo F Montenegro; José E Tanus-Santos; Silvana R P Orrico; Joni A Cirelli
Journal:  Int J Mol Sci       Date:  2017-06-15       Impact factor: 5.923

Review 7.  Preeclampsia, Natural History, Genes, and miRNAs Associated with the Syndrome.

Authors:  Laura Parada-Niño; Luisa Fernanda Castillo-León; Adrien Morel
Journal:  J Pregnancy       Date:  2022-02-14

8.  Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia.

Authors:  Lorena M Amaral; Lucas C Pinheiro; Danielle A Guimaraes; Ana C T Palei; Jonas T Sertório; Rafael L Portella; Jose E Tanus-Santos
Journal:  J Cell Mol Med       Date:  2013-07-24       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.